News
PathoQuest Appoints Colette Côté as Chief Portfolio Officer and General Manager of the Company’s U.S. Subsidiary
Annoucement of the appointment of Colette Côté, Ph.D. as Chief Portfolio Officer and General Manager of PathoQuest’s U.S. subsidiary located in Wayne, PA. Ms. Côté’s expertise and long history of innovating, developing, and applying tailored NGS-based assays to the biopharma biosafety testing space will further drive the expansion and growth of PathoQuest’s NGS-based services portfolio within the North American market.
Meet Courtney Cambouris our new NGS specialist!
Dr. Courtney Cambouris previously worked worked with customers all over the United States and several countries in Europe in her former role in sales and product management. Join us to welcome her as she is joining PathoQuest as a Sales Manager and bringing her NGS expertise to the biologics services customers.
Happy International Women’s Day | 8th March
They are CSO, Account managers, Chief regulatory affairs officer, Technicians, R&D engineers, Study director….and they represent 58% of PathoQuest talented employees. We are proud to support professional gender equality on this specific day but also throughout the year. Come and check the career paths at PathoQuest
Viral Safety Expert, Audrey Brussel, joins PathoQuest
PathoQuest announces the appointment of Audrey Brussel, Ph.D. to the newly created position of Viral Safety Leader. Her addition to the company will strengthen PathoQuest’s in-house expertise in viral safety. Her insights and knowledge of the pharmaceutical industry from a customer’s perspective will help deliver a better service and support the growth of the company’s rapidly expanding quality control testing business for biologics.
PathoQuest Announces Appointment of Laurent Lafferrere as Chief Operating Officer
PathoQuest announced the appointment of Dr. Laurent Lafferrere as company COO. Dr. Laurent Lafferrère has over 20 years of experience in the pharmaceutical industry, in CMC divisions, including 10 years of experience in executive management.
Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ a platform for recombinant viral vector manufacturing.
Transgene is a French biotechnology company focused on designing and developing next generation immunotherapeutics. In these phase 1 trials with 85 patients, Transgene has chosen PathoQuest next generation sequencing (NGS) solutions for its fast and cost-effective viral safety testing approach of the product.
Pick another category:
Click here to learn more about PathoQuest’s Biologics Genomic Service for biopharmaceutical companies.
Connect